Premium
Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate
Author(s) -
Isobe Y.,
Sugimoto K.,
Masuda A.,
Hamano Y.,
Oshimi K.
Publication year - 2009
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2009.01947.x
Subject(s) - medicine , imatinib mesylate , blast crisis , chronic myelogenous leukemia , central nervous system , imatinib , bacterial meningitis , meningitis , leukemia , immunology , surgery , myeloid leukemia
Imatinib mesylate (IM) is currently used as the first therapeutic choice against chronic myelogenous leukaemia (CML). Because IM poorly penetrates the blood‐brain barrier, IM‐treated CML patients may have a potential risk of central nervous system (CNS) involvement. Here we report a case with lymphoid blast crisis isolated only in CNS after bacterial meningitis, although the patient achieved and maintained complete cytogenetic response by IM therapy. It is important to consider isolated CNS blast crisis as a possible event in IM‐treated CML patients.